10
Participants
Start Date
April 30, 2013
Primary Completion Date
April 30, 2016
Study Completion Date
October 31, 2017
Omalizumab
Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
University of Colorado Hospital, Denver
Collaborators (1)
University of Colorado, Denver
OTHER
Genentech, Inc.
INDUSTRY